Innovating today the therapies of tomorrow
Welcome to Adamed Discovery, the innovation engine of the Adamed Group. Built on nearly four decades of unwavering commitment to scientific progress and public health, we are a family-owned, research-based pharmaceutical and biotechnology company with 100% Polish capital.
Our mission is clear:
to pioneer first-in-class therapeutics
that address the root causes of serious diseases and set
new standards of care.
Key Highlights
We combine deep biological insight with translational expertise to drive breakthroughs in oncology and CNS. Our dedicated scientists continuously push boundaries with ongoing R&D investments.
This commitment has built a portfolio across 19 therapeutic areas, protected by over 160 global patent families.Explore Our Pipeline
Adamed Discovery is focused on advancing first-in-class therapeutics in oncology and CNS through deep biological insight and translational expertise. Currently, we have 5 active projects in progress, with plans to initiate 3 additional projects in 2026.
Expertise & Technologies
At Adamed Discovery, we leverage deep
domain expertise and advanced technologies
to develop novel therapeutics
in oncology and CNS
Partnerships & Grants
Our ambitious mission to develop first-in-class therapeutics is significantly amplified through a robust network of strategic partnerships and vital scientific collaborations.
These alliances are not just connections; they are fundamental to our success, extending our reach, enhancing our capabilities, and accelerating our progress in areas of high unmet medical need, particularly within oncology and CNS disorders.